FCN-159 is under clinical development by Fochon Pharmaceutical and currently in Phase II for Neurofibromatoses Type I (Von Recklinghausen’s Disease). According to GlobalData, Phase II drugs for Neurofibromatoses Type I (Von Recklinghausen’s Disease) have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how FCN-159’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

FCN-159 overview

FCN-159 is under development for the treatment of solid tumors including metastatic melanoma, relapsed or advanced low-grade glioma and neurofibromatosis type 1 in adults and pediatrics. It is also under development for Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD), other histiocytic tumors and extracranial arteriovenous malformations. It is administered through oral route in the form of tablet. The drug candidate acts by targeting the enzyme MEK1 and MEK2.

Fochon Pharmaceutical overview

Chongqing Fochon Pharmaceutical Co., Ltd. is engaged in the research and development of chemical drugs.

For a complete picture of FCN-159’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.